Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

Must have received: systemic therapy — advanced cholangiocarcinoma

Participants must have failed 1 line of systemic regimens for advanced cholangiocarcinoma due to disease progression or toxicity.

Cannot have received: cryoablation

Prior treatment with cryoablation.

Cannot have received: radiofrequency ablation

Exception: if administered less than 4 weeks prior to study treatment start

RFA and resection administered less than 4 weeks prior to study treatment start.

Cannot have received: surgical resection

Exception: if administered less than 4 weeks prior to study treatment start

RFA and resection administered less than 4 weeks prior to study treatment start.

Cannot have received: radiotherapy

Exception: if administered less than 4 weeks prior to study treatment start

Radiotherapy administered less than 4 weeks prior to study treatment start.

Cannot have received: major surgery

Exception: if within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery

Major surgery within 4 weeks of starting the study treatment OR subjects who have not recovered from effects of major surgery.

Cannot have received: anti-CD137 antibody

Prior therapy with an anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor (TNFR) family)

Cannot have received: anti-CTLA-4 antibody (ipilimumab)

Prior therapy with ... anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).